within Pharmacolibrary.Drugs.N_NervousSystem.N02B_OtherAnalgesicsAndAntipyretics.N02BA01_AcetylsalicylicAcid;

model AcetylsalicylicAcid
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.68,
    Cl = 1.1111111111111112e-05,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.00016,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0014666666666666667,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>AcetylsalicylicAcid</td></tr><tr><td>ATC code:</td><td>N02BA01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.16</td><td>L</td></tr>
    <tr><td>clearance:</td><td>40</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Acetylsalicylic acid, commonly known as aspirin, is a nonsteroidal anti-inflammatory drug (NSAID) used primarily as an analgesic, antipyretic, and anti-inflammatory agent. It is also used as an antiplatelet agent for the prevention of cardiovascular events such as myocardial infarction and stroke. Aspirin is approved and widely used today for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers, following a single oral dose.</p><h4>References</h4><ol><li><p>Fager, G, et al., &amp; Eriksson, UG (2003). Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. <i>European journal of clinical pharmacology</i> 59(4) 283–289. DOI:<a href=\"https://doi.org/10.1007/s00228-003-0619-x\">10.1007/s00228-003-0619-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12845508/\">https://pubmed.ncbi.nlm.nih.gov/12845508</a></p></li><li><p>Brouwers, JR, &amp; de Smet, PA (1994). Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. <i>Clinical pharmacokinetics</i> 27(6) 462–485. DOI:<a href=\"https://doi.org/10.2165/00003088-199427060-00005\">10.2165/00003088-199427060-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7882636/\">https://pubmed.ncbi.nlm.nih.gov/7882636</a></p></li><li><p>Stephen, LJ (2003). Drug treatment of epilepsy in elderly people: focus on valproic Acid. <i>Drugs &amp; aging</i> 20(2) 141–152. DOI:<a href=\"https://doi.org/10.2165/00002512-200320020-00005\">10.2165/00002512-200320020-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12534314/\">https://pubmed.ncbi.nlm.nih.gov/12534314</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N02BA01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end AcetylsalicylicAcid;
